Lipocine Inc. (NASDAQ: LPCN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
Lipocine Inc. (NASDAQ: LPCN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Lipocine Inc. (NASDAQ: LPCN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Cirrhosis Market and Pipeline Insights, 2024: Analysis of Emerging Drugs GXHPC 1 (GWOXI Stem Cell Applied Technology), LPCN 1148 (Lipocine), and Belapectin (Galectin Therapeutics) [Yahoo! Finance]